by Robert W. Chandler, MD, MBA, Daily Clout:
Albert Benavides has diligently documented techniques used by public health agencies to hide data in their databases. He has exposed the techniques of throttling, time displacement, and removal of all or parts of reports. Mr. Benavides posts frequently on Substack.
This report will examine two cases drawn from Vaccine Adverse Event Reporting System (VAERS), maintained by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), that exemplify two phenomena, possibly intentional tactics, that in effect hide important information from the public.
TRUTH LIVES on at https://sgtreport.tv/
1) Time Displacement:
This query of the VAERS Wonder database and results for COVID19 and COVID19-2 for the United States and Territories for the year 2001 demonstrates time displacement.
According to U.S. government data, 97 events were reported for COVID19 vaccine administered in the year 2001. However, a COVID19 vaccine did not exist in 2001.
What types of events were reported for COVID19 vaccines allegedly injected in 2001?
The query criteria included: Year 2001, United States and Territories, Event Category, and Vaccine.
And the result:
This query returned 112 adverse events from COVID19 vaccines in 2001 including: one congenital anomaly/birth defect, two deaths, two cases of permanent disability, and three life-threatening events.
What is going on? To find out, let us look at a case selected randomly from the list of VAERS IDs in this collection of events reported after alleged injections of COVID19 vaccines in 2001.
VAERS #1512205 was a 39-year old-male who suffered a cerebral venous thrombosis (CVT) following injection with Janssen’s (Johnson and Johnson) COVID19 drug that was reportedly injected 7,405 days before symptoms developed (see screenshots below). Interesting. Did someone take the time to calculate this number of days, or is it done by algorithm? Are any of the reported dates accurate? It is not possible to know based on the data given.
What is cerebral venous thrombosis? According to the American Heart Association in their updated AHD Scientific Statement March 2024:
“Cerebral venous thrombosis (CVT) is the presence of a blood clot in the dural venous sinuses, the cerebral veins, or both. Among those with stroke, CVT represents only 0.5% to 3%.2 Registry-based and cohort studies suggest that CVT affects predominantly individuals <55 years of age, with two-thirds occurring in women.” [Saposnik G, Bushnell C, Coutinho JM, Field TS, Furie KL, Galadanci N, Kam W, Kirkham FC, McNair ND, Singhal AB, Thijs V, Yang VXD; on behalf of the American Heart Association Stroke Council; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke. 2024;55:e77–e90. doi: 10.1161/STR.0000000000000456]
A blood clot in a major vein in the brain presents with headache in about 90 percent of cases. [[Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004; 35:664–670. doi: 10.1161/01.STR.0000117571] Other findings include nausea, vision disturbances, elevation of intracranial pressure, seizure, encephalopathy, and coma. [Saposnik G, Bushnell C, Coutinho JM, Field TS, Furie KL, Galadanci N, Kam W, Kirkham FC, McNair ND, Singhal AB, Thijs V, Yang VXD; on behalf of the American Heart Association Stroke Council; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke. 2024;55:e77–e90. doi: 10.1161/STR.0000000000000456]
